Larimar Therapeutics files common stock, warrants offering

Larimar Therapeutics announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock. Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, including research and development expenses. Leerink Partners, Citigroup and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering.